semaglutide fda warning Compounded "semaglutide" is not FDA-approved The FDA and the maker

Mounjaro is not appropriate for everyone

[DOI] [PMC free article] [PubMed] [Google Scholar] 146.Lean M.E., Carraro R., Finer N., Hartvig H., Lindegaard M.L., Rossner S., et al

What has been documented from these sources includes: Headaches, typically described as dull and short-lived Dizziness or light-headedness, particularly after injection Nausea or mild digestive discomfort, more common with oral forms Injection-site reactions including redness, swelling and irritation Appetite changes, sometimes reported as increased hunger Disrupted sleep when dosed in the evening Less commonly, palpitations or mood changes None of these has been formally linked to BPC-157 in peer-reviewed human studies

Even with costsharing strategies such as copayments, the impact on premiums is minimal